ClinicalTrials.gg
CompletedNCT01223352FUTURE 3Updated Feb 4, 2025Results posted

Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension

A Phase 3 interventional study of bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
3 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
4th of 18
64 · median 37
Started
2011
with 2 others
Phase 3
7 of 18
none open now
Registered
11th of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 11th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 3 Months to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) \<12 years of age.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • children
  • pediatric
  • bosentan
04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PAH diagnosis confirmed with right heart catheterization (RHC):

    • Idiopathic or heritable PAH, or
    • Associated PAH persisting after complete repair of a congenital heart defect (PAH has to be persistent for at least 6 months after surgery) or
    • PAH-Congenital Heart Disease (PAH-CHD) associated with systemic-to-pulmonary shunts (after global amendment dated 09 May 2012)
  2. World Health Organization functional Class (WHO FC) I, II or III
  3. Male or female ≥ 3 months and \< 12 years of age (maximum age at randomization is 11.5 years)
  4. Body weight ≥ 3.5 kg
  5. Peripheral oxygen saturation (SpO2) ≥ 88% (at rest, on room air)
  6. Baseline PAH-therapy (Calcium channel blocker, bosentan, prostanoid, phosphodiesterase type-5 inhibitor) if present, has to be stable for at least 3 months prior to screening. During the study, all background treatments should remain stable
  7. Signed by the parents or legal representatives

Exclusion criteria

Exclusion Criteria:

  1. PAH etiologies other than listed above
  2. Non-stable disease status
  3. Need or plan to wean patient from intravenous epoprostenol or intravenous or inhaled iloprost
  4. Systolic blood pressure \< 80% of the lower limit of normal range
  5. and/or alanine aminotransferase values > 1.5 times the .
  6. Moderate to severe hepatic impairment, i.e., Class B or C
  7. and/or hematocrit levels \< 75% of the lower limit of normal range.
  8. Known intolerance or to bosentan or any of the of the dispersible Tracleer tablet
  9. Treatment with forbidden medication within 2 weeks or at least 5 times the half-life prior to randomization, whichever is the longest:

    • Glibenclamide (glyburide)
    • Cyclosporin A
    • Sirolimus
    • Tacrolimus
    • Fluconazole
    • Rifampicin (rifampin)
    • Ritonavir
    • Co-administration of CYP2C9 inhibitors (e.g., amiodarone, voriconazole) and moderate/strong inhibitors (e.g., amprenavir, erythromycin, ketoconazole, diltiazem, itraconazole)
    • Endothelin receptor antagonists (ERAs) other than bosentan
  10. Treatment with another drug within 1 month prior to randomization or planned treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Bosentan 2 mg/Kg t.i.d.

    2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks

    Drug: bosentan

  • Experimental
    Bosentan 2 mg/Kg b.i.d.

    2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks

    Drug: bosentan

Interventions

  • 32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.

    Also known as: Tracleer, ACT-050088

06

What researchers measure

Primary outcomes

  1. Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan

    Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours \[AUC(0-24)\]. Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau, which is the AUC over a dosing interval (AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen). As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].

    Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment

Other outcomes

  1. Dose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan

    Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. The peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).

    Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment

  2. Time to Reach Cmax [Tmax] of Bosentan

    Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. tmax was obtained directly from the measured plasma concentrations.

    Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment

  3. Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan Metabolites (Ro 478634, Ro 485033, Ro 641056)

    Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve \[AUC(0-24)\] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].

    Time frame: 0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment

  4. Change From Baseline in WHO Functional Class at End of Study

    The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension (PH): Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class IIII (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.

    Time frame: Baseline, up to Week 24 on average

  5. Change From Baseline in Global Clincial Impression Scale (GCIS) at End of Study

    The GCIS is an assessment tool providing a single global assessment of the patient's current overall clinical condition: Very Good, Good, Neither Good or Bad, Bad and Very Bad. The assessment was performed both by the physician and the parents / legal representatives independently. Global clinical impression (GCI) at end of study was compared to GCI at baseline and the number of patients with clinical condition considered as worsened, improved or unchanged are determined.

    Time frame: Baseline, up to Week 24 on average

  6. Number of Patients With Treatment-emergent Liver Function Abnormalities

    Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.

    Time frame: Baseline, up to Week 24

  7. Number of Patients With Treatment-emergent Hemoglobin Abnormalities

    Number of patients with marked hemoglobin decreases (absolute values below 10 g/dL). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.

    Time frame: Baseline, up to Week 24

07

Results

Posted Jun 29, 2017

Participant flow

Forty-five expert pediatric centers were initiated but only thirty of them enrolled children with pulmonary arterial hypertension (PAH)

Participant flow — Overall Study
MilestoneBosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.
Started3133
Completed3133
Not completed00

Outcome measures

PrimaryDose-corrected Daily Exposure [AUC(0-24c)] to Bosentan

Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours \[AUC(0-24)\]. Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau, which is the AUC over a dosing interval (AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen). As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].

Time frame:
0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Reported as:
Geometric mean · h*ng/mL
Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan
h*ng/mLBosentan 2 mg/kg t.i.d. (PK Set)Bosentan 2 mg/kg b.i.d. (PK Set)
Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan7275.1 (5468.2 to 9679.0)8535.4 (6936.0 to 10503.7)
Statistical analysis
  • Bosentan 2 mg/kg t.i.d. (PK Set) vs Bosentan 2 mg/kg b.i.d. (PK Set) · Ratio of geometric means: 0.85 · 95% CI 0.61 to 1.20b.i.d. bosentan regimen was taken as reference
Other pre-specifiedDose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan

Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. The peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).

Time frame:
0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Reported as:
Geometric mean · ng/mL
Dose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan
ng/mLBosentan 2 mg/kg t.i.d. (PK Set)Bosentan 2 mg/kg b.i.d. (PK Set)
Dose-corrected Maximum Plasma Concentration [Cmaxc] of Bosentan527.9 (386.0 to 721.9)742.8 (572.8 to 963.2)
Statistical analysis
  • Bosentan 2 mg/kg t.i.d. (PK Set) vs Bosentan 2 mg/kg b.i.d. (PK Set) · Ratio of geometric means: 0.71 · 95% CI 0.48 to 1.05b.i.d. bosentan regimen was taken as reference
Other pre-specifiedTime to Reach Cmax [Tmax] of Bosentan

Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. tmax was obtained directly from the measured plasma concentrations.

Time frame:
0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Reported as:
Median · hours
Time to Reach Cmax [Tmax] of Bosentan
hoursBosentan 2 mg/kg t.i.d. (PK Set)Bosentan 2 mg/kg b.i.d. (PK Set)
Time to Reach Cmax [Tmax] of Bosentan3 (1 to 8)3 (0 to 7.5)
Other pre-specifiedDose-corrected Daily Exposure [AUC(0-24c)] to Bosentan Metabolites (Ro 478634, Ro 485033, Ro 641056)

Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve \[AUC(0-24)\] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) \[AUC(0-24c)\].

Time frame:
0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment
Reported as:
Geometric mean · h*ng/mL
Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan Metabolites (Ro 478634, Ro 485033, Ro 641056)
h*ng/mLBosentan 2 mg/kg t.i.d. (PK Set)Bosentan 2 mg/kg b.i.d. (PK Set)
AUC(0-24C) for Ro 478634173.2 (126.2 to 237.6)200.4 (152.2 to 263.9)
AUC(0-24C) for Ro 485033968.8 (723.3 to 1297.7)1352.5 (1073.4 to 1704.0)
AUC(0-24C) for Ro 641056716.2 (543.5 to 943.8)1014.1 (801.2 to 1283.6)
Other pre-specifiedChange From Baseline in WHO Functional Class at End of Study

The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension (PH): Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class IIII (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.

Time frame:
Baseline, up to Week 24 on average
Reported as:
Number · Participants
Change From Baseline in WHO Functional Class at End of Study
ParticipantsBosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d
Worsened WHO FC11
Unchanged WHO FC2725
Improved WHO FC37
Other pre-specifiedChange From Baseline in Global Clincial Impression Scale (GCIS) at End of Study

The GCIS is an assessment tool providing a single global assessment of the patient's current overall clinical condition: Very Good, Good, Neither Good or Bad, Bad and Very Bad. The assessment was performed both by the physician and the parents / legal representatives independently. Global clinical impression (GCI) at end of study was compared to GCI at baseline and the number of patients with clinical condition considered as worsened, improved or unchanged are determined.

Time frame:
Baseline, up to Week 24 on average
Reported as:
Number · Participants
Change From Baseline in Global Clincial Impression Scale (GCIS) at End of Study
ParticipantsBosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.
Worsened as per physician evaluation22
Worsened as per parents evaluation43
Unchanged as per physician evaluation2424
Unchanged as per parents evaluation1919
Improved as per physician evaluation57
Improved as per parents evaluation811
Other pre-specifiedNumber of Patients With Treatment-emergent Liver Function Abnormalities

Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 times upper limit of normal (ULN). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.

Time frame:
Baseline, up to Week 24
Reported as:
Number · Participants
Number of Patients With Treatment-emergent Liver Function Abnormalities
ParticipantsBosentan 2 mg/kg t.i.d. (ITT Set)Bosentan 2 mg/kg b.i.d. (ITT Set)
ALT > 3 x ULN10
AST > 3 x ULN00
Other pre-specifiedNumber of Patients With Treatment-emergent Hemoglobin Abnormalities

Number of patients with marked hemoglobin decreases (absolute values below 10 g/dL). The worst post-baseline value was considered. The treatment-emergent period was defined as study treatment start date up to 7 calendar days after study treatment end date.

Time frame:
Baseline, up to Week 24
Reported as:
Number · Participants
Number of Patients With Treatment-emergent Hemoglobin Abnormalities
ParticipantsBosentan 2 mg/kg t.i.d. (ITT Set)Bosentan 2 mg/kg b.i.d. (ITT Set)
Hemoglobin decrease with values < 10 g/dL13
Hemoglobin decrease with values < 8 g/dL00

Adverse events

Collected over From the first dose of study treatment on Day 1 up to 7 days after treatment discontinuation, i.e. up to Week 25 on average. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan 2 mg/kg t.i.d—6/31 (19.4%)18/31 (58.1%)
Bosentan 2 mg/kg b.i.d—4/33 (12.1%)18/33 (54.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventBosentan 2 mg/kg t.i.dBosentan 2 mg/kg b.i.d
ATRIAL SEPTAL DEFECT REPAIRSurgical and medical procedures1/310/33
BODY TEMPERATURE INCREASEDInvestigations1/310/33
BRONCHOPNEUMONIAInfections and infestations1/310/33
GASTROENTERITISInfections and infestations1/310/33
OXYGEN SATURATION DECREASEDInvestigations1/310/33
PULMONARY ARTERIAL HYPERTENSIONRespiratory, thoracic and mediastinal disorders1/311/33
PYREXIAGeneral disorders1/310/33
RESPIRATORY DISTRESSRespiratory, thoracic and mediastinal disorders1/310/33
RESPIRATORY TRACT INFECTION VIRALInfections and infestations1/310/33
VIRAL INFECTIONInfections and infestations1/310/33
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBosentan 2 mg/kg t.i.dBosentan 2 mg/kg b.i.d
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations11/316/33
PYREXIAGeneral disorders6/314/33
NASOPHARYNGITISInfections and infestations3/315/33
DIARRHOEAGastrointestinal disorders4/312/33
VOMITINGGastrointestinal disorders4/311/33
COUGHRespiratory, thoracic and mediastinal disorders3/310/33
EPISTAXISRespiratory, thoracic and mediastinal disorders3/310/33
CONSTIPATIONGastrointestinal disorders2/311/33
FLUSHINGVascular disorders2/310/33
RASHSkin and subcutaneous tissue disorders2/311/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.Total
Mean5.2 ± 3.814.5 ± 3.354.8 ± 3.57
Sex: Female, Male
Sex: Female, Male(Participants)Bosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.Total
Female101828
Male211536
Region of Enrollment
Region of Enrollment(Participants)Bosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.Total
Australia202
Belarus123
China246
Czech Republic112
France145
Germany314
Hungary303
India123
Israel022
Italy101
Mexico101
Poland235
Russia4610
Serbia235
South Africa426
Spain123
USA112
Ukraine101
Etiology of pulmonary arterial hypertension (PAH)
Etiology of pulmonary arterial hypertension (PAH)(Participants)Bosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.Total
Idiopathic151429
Heritable022
PAH-Congenital heart disease268
Associated PAH131124
Missing data101
World Health Organization functional class (WHO FC)
World Health Organization functional class (WHO FC)(Participants)Bosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.Total
FC I10919
FC II151227
FC III61218
PAH-specific therapy at baseline
PAH-specific therapy at baseline(Participants)Bosentan 2 mg/kg t.i.d.Bosentan 2 mg/kg b.i.d.Total
Bosentan (adult tablet formulation)437
Prostanoid101
Phosphodiesterase type-5 (PDE-5) inhibitor131023
Bosentan / PDE-5 inhibitor combination224
Bosentan /PDE-5 inhibitor /Prostanoid combination257
None91322
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Apr 2013, 24 months.

Results were first posted in Jun 2017, 4 years 2 months after primary completion. A results delay was requested in Aug 2014.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 24 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2010
First posted
Oct 19, 2010
StartActual
Mar 8, 2011
Primary completionActual
Apr 3, 2013
CompletionActual
Aug 19, 2013
Results delay requested
Aug 22, 2014
Results first posted
Jun 29, 2017
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01223352
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Oct 19, 2010
Start date
Mar 8, 2011
Primary completion
Apr 3, 2013
Completion
Aug 19, 2013
Results posted
Jun 29, 2017
Last update
Feb 4, 2025

Study contacts

Andjela Kusic-Pajic, MD
study director · Actelion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion